Pulmonary cryptococcosis after immunomodulator treatment in patients with Crohn's disease: Three case reports

Background: Corticosteroids and anti-tumor necrosis factor α mAbs are widely used to treat Crohn's disease (CD). However, one disadvantage of this treatment is impairment of normal immune function, leading to an increased risk of infection. Cryptococcus infection is an opportunistic infection that occurs mainly in immunocompromised patients and poses a significant diagnostic challenge in patients with CD.

Case summary: Here, we report three cases of pulmonary cryptococcosis in patients with CD after receiving immunomodulatory treatment. The patients presented with no or mild respiratory symptoms. Chest computed tomography scans revealed pulmonary nodules in the unilateral or bilateral lobes. Diagnoses were made using pathological examination and metagenomic sequencing. The patients were treated with fluconazole 400 mg once daily for 1 to 6 mo, and symptoms were resolved. Literature searches were conducted in PubMed, Web of Science, and Embase to retrieve previously reported cases and summarize patient characteristics.

Conclusion: The incidence of cryptococcus infection has increased along with immunomodulator use. Clinical vigilance is required for early identification and standardized treatment.

Comments：

Three patients with Crohn's disease on immunomodulatory treatment developed pulmonary cryptococcosis with mild symptoms and resolved with fluconazole treatment, highlighting the importance of clinical vigilance for early identification and treatment of opportunistic infections in immunocompromised patients.

Related Products

Cat.No.	Product Name	Information
S1331	Fluconazole	Fluconazole is a fungal lanosterol 14 alpha-demethylase inhibitor, which thereby prevents the formation of ergosterol,used in the treatment and prevention of superficial and systemic fungal infections.

Related Targets

Fungal P450 (e.g. CYP17)